Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
基本信息
- 批准号:8792437
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2016-02-18
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAgitationAminopterinAreaBiological AssayBiological MarkersBiological Response Modifier TherapyCanis familiarisCaringChronicChronic small plaque psoriasisClinicClinicalClinical ResearchCoupledCyclic GMPDHFR geneDNADisease remissionDisorientationDoseEffectivenessFailureFatigueFeelingFolateFolic Acid AntagonistsGeneticHeadacheHepatotoxicityHumanIn VitroInflammationInflammatoryIntestinesIsoenzymesLegal patentLiverMarketingMemory impairmentMethodsMethotrexateMitochondriaMusNuclearOralPatientsPharmaceutical EconomicsPharmaceutical PreparationsPhase II Clinical TrialsPhototherapyPlacebo ControlPlacebosPopulationPricePropertyProtonsPsoriasisReactionRelapseRelative (related person)ReportingResistanceRestRiskSafetySeveritiesTestingThymidylate SynthaseTimeToxic effectTranslatingUnited StatesUracilbasecellular developmentcostenantiomerexperienceimprovedin vivoindexingmeetingsnovelplacebo controlled studypreclinical studypublic health relevanceresistance mechanismresponseskin disorderuptake
项目摘要
DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resulting in total annual costs of $5.2 billion in the United States in 2012. Approximately 20% of patients with moderate-to-severe chronic plaque psoriasis require phototherapy and/or a variety of systemic treatments, where methotrexate (MTX) is the mostly widely used oral systemic agent. Despite the relative effectiveness of MTX, as a monotherapy, it does not achieve greater than a 75% reduction in the baseline psoriasis area-and-severity index (PASI 75) in 40% of patients, and fails to achieve remission (i.e. > PASI 90) in 60% of patients. Furthermore, up to 30% of patients with moderate-to-severe plaque psoriasis discontinue oral MTX primarily because of intolerance to the drug. While much effort has been directed to identifying the mechanism behind poor and/or toxic responses to MTX based on genetic factor and quantitation of its active metabolites, the majority of MTX failures remain unexplained. Given the efficacy and safety limitations of MTX and the cost of biologics compared to MTX (~$20,000 vs. $300 per year), there is a clear market opportunity for an improved antifolate with better efficacy and/or safety than MTX, but that is priced between MTX and biologics. LD-Aminopterin (LD-AMT) is a patented composition developed by Syntrix Biosystems that studies indicate has greater cellular uptake (i.e. polyglutamylation to the active metabolites) than MTX, and less liver and CNS toxicity, properties that may translate into better efficacy and/or safety. In addition to identifying LD-AMT as a potential improvement on MTX, gaining a mechanistic understanding of antifolate resistance in general has important clinical implications for treating inflammation with LD-AMT or MTX, by possibly identifying clinical biomarkers to predict optimal response or risk of toxicity in advance of initiating treatment. This U44 Fast-Track proposal aims to advance LD-AMT to the clinic by testing LD-AMT for efficacy in a placebo-controlled phase 2 trial and advancing a novel hypothesis-driven mechanistic explanation for antifolate resistance.
描述(由申请人提供):银屑病是一种慢性、遗传影响、缓解和复发的鳞状和炎性皮肤病,影响世界人口的1-3%,导致2012年美国的年度总成本为52亿美元。大约20%的中重度慢性斑块状银屑病患者需要光疗和/或各种全身性治疗,其中甲氨蝶呤(MTX)是最广泛使用的口服全身性药物。尽管MTX作为单药治疗具有相对有效性,但在40%的患者中,其基线银屑病面积和严重程度指数(PASI 75)的降低不超过75%,并且在60%的患者中未能实现缓解(即> PASI 90)。此外,高达30%的中重度斑块状银屑病患者主要由于对药物不耐受而停止口服MTX。虽然许多努力已经针对基于遗传因素和其活性代谢物的定量来确定对MTX的不良和/或毒性反应背后的机制,但大多数MTX失败仍然无法解释。考虑到MTX的疗效和安全性限制以及与MTX相比生物制剂的成本(每年约20,000美元对300美元),具有比MTX更好疗效和/或安全性的改良抗叶酸剂存在明显的市场机会,但其价格介于MTX和生物制剂之间。LD-氨基蝶呤(LD-AMT)是Syndrome Biosystems开发的一种专利组合物,研究表明其比MTX具有更高的细胞摄取(即活性代谢物的聚谷氨酰化),以及更低的肝脏和CNS毒性,这些特性可能转化为更好的疗效和/或安全性。除了将LD-AMT鉴定为MTX的潜在改善之外,获得抗叶酸剂抗性的机制性理解通常对于用LD-AMT或MTX治疗炎症具有重要的临床意义,其可能通过鉴定临床生物标志物来预测最佳反应或在开始治疗之前的毒性风险。这项U44快速通道提案旨在通过在安慰剂对照的2期试验中测试LD-AMT的疗效,并提出一种新的假设驱动的抗叶酸剂耐药性机制解释,将LD-AMT推向临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART J KAHN其他文献
STUART J KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART J KAHN', 18)}}的其他基金
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10372803 - 财政年份:2019
- 资助金额:
$ 22.5万 - 项目类别:
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10029002 - 财政年份:2019
- 资助金额:
$ 22.5万 - 项目类别:
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
HLS-SX-682 在 MDS 患者中的 1 期开放标签剂量递增和扩展研究
- 批准号:
9789451 - 财政年份:2018
- 资助金额:
$ 22.5万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
10189528 - 财政年份:2017
- 资助金额:
$ 22.5万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9348033 - 财政年份:2017
- 资助金额:
$ 22.5万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9755385 - 财政年份:2017
- 资助金额:
$ 22.5万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
8981655 - 财政年份:2015
- 资助金额:
$ 22.5万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
9317459 - 财政年份:2015
- 资助金额:
$ 22.5万 - 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
- 批准号:
9188625 - 财政年份:2014
- 资助金额:
$ 22.5万 - 项目类别:
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers
克服 CYP2D6 代谢不良者的曲马多耐药性
- 批准号:
8713969 - 财政年份:2010
- 资助金额:
$ 22.5万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




